January 17, 2019
Innovent Biologcs testing potential of sintilimab in combination with chemotherapy in ORIENT-16, a phase III trial, on gastric cancer patients
Innovent Biologics has started testing on patients its Tyvyt, fully human anti-PD-1 therapeutic monoclonal antibody, with generic name sintilimab injection, in combination with capecitabine and oxaliplatin, patients with advanced, recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma (GC or GEJ).